文献速递消化道肿瘤放疗放疗物理与技术

局部晚期胰腺癌碳离子放疗的多机构研究:日本碳离子放射肿瘤学研究组(J-CROS)1403胰腺研究

Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-05-01

本研究多机构回顾性分析了2012年4月至2014年12月3家机构收治的72例局部晚期胰腺癌患者,接受52.8 Gy(RBE)或55.2 Gy(RBE)分12次碳离子放疗。中位总生存21.5个月,1年总生存率73%,急性3/4级血液学毒性19例(26%),晚期3级胃肠道毒性1例(1%),无晚期4/5级毒性。

要点

  • 72例局部晚期胰腺癌患者接受碳离子放疗,中位总生存21.5个月,1年总生存率73%。
  • 急性3/4级血液学毒性19例(26%),晚期3级胃肠道毒性1例(1%),无晚期4/5级毒性。
  • 结论认为碳离子放疗 outcomes 相对良好且毒性有限,尤其适用于肿瘤未紧邻胃肠道的情况。

核心结论

  • 碳离子放疗对局部晚期胰腺癌显示出相对良好的结局和有限的毒性,尤其对于肿瘤未紧邻胃肠道的患者。

研究设计与样本

  • 多机构回顾性分析,纳入2012年4月至2014年12月3家机构收治的病理确诊胰腺浸润性导管腺癌局部晚期患者72例。
  • 处方剂量为52.8 Gy(RBE)或55.2 Gy(RBE),分12次照射。
  • 评估总生存、无远处转移生存、局部复发和毒性。

主要发现

  • 肿瘤位于胰头30例(42%),位于胰体或胰尾42例(58%);56例(78%)接受同步化疗。
  • 1年总生存率73%(95%CI 62%-84%),2年总生存率46%(95%CI 31%-61%),中位总生存21.5个月(95%CI 11.8-31.2个月)。
  • 1年和2年无远处转移生存率分别为41%(95%CI 29%-52%)和28%(95%CI 16%-40%)。
  • 1年和2年局部复发累积发生率分别为16%(95%CI 9%-26%)和24%(95%CI 14%-36%)。
  • 急性3或4级血液学毒性19例(26%),3级厌食2例(3%);晚期3级胃肠道毒性1例(1%),无晚期4或5级毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this multi-institutional study was to evaluate the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally advanced pancreatic cancer (LAPC). METHODS AND MATERIALS: Patients with LAPC treated with C-ion RT from April 2012 to December 2014 at 3 institutions were retrospectively analyzed. Patients with pathologically-confirmed invasive ductal adenocarcinoma of the pancreas were eligible. The prescribed dose was 52.8 Gy (relative biological effectiveness weighted absorbed dose; RBE) or 55.2 Gy (RBE) in 12 fractions. Overall survival (OS), distant metastasis-free survival (DMFS), local recurrence (LR), and toxicity were evaluated. RESULTS: In total, 72 patients were included in this study. Tumors in the head of the pancreas were seen in 30 patients (42%), while those in the body or tail of the pancreas were seen in 42 patients (58%). Fifty-six patients (78%) received concurrent chemotherapy. The OS rates were 73% (95% confidence interval [CI], 62%-84%) at 1 year, and 46% (95% CI, 31%-61%) at 2 years with a median OS of 21.5 months (95% CI, 11.8-31.2 months). The 1- and 2-year DMFS rates were 41% (95% CI, 29%-52%) and 28% (95% CI, 16%-40%), respectively. The 1- and 2-year cumulative incidences of LR were 16% (95% CI, 9%-26%) and 24% (95% CI, 14%-36%), respectively. Nineteen patients (26%) experienced acute grade 3 or 4 hematological toxicities. Two patients (3%) had grade 3 anorexia. Late gastrointestinal (GI) grade 3 toxicity was observed in 1 patient (1%). No patients developed late grade 4 or 5 toxicity. CONCLUSIONS: The first multi-institutional analysis of C-ion RT for LAPC indicated relatively favorable outcomes with limited toxicities, especially for tumors not in close proximity to GI tract.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kawashiro S, Yamada S, Okamoto M, et al. Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas. Int J Radiat Oncol Biol Phys. 2018. PMID: 29907490. doi:10.1016/j.ijrobp.2018.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。